Capecitabine plus lenvatinib for advanced colorectal cancer
Part of Cancer clinical trials.
This trial tests a combination of two oral drugs, capecitabine and lenvatinib, in people with advanced colorectal cancer that has stopped responding to three common chemotherapy drugs. It aims to see if this new combination can help shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal cancer that has stopped responding to irinotecan, oxaliplatin, and fluoropyrimidine chemotherapy.
- You must be 19 years or older and give written consent.
- You must be in reasonably good health, with adequate blood counts, kidney and liver function.
- You must not be pregnant or breastfeeding, and if able to have children, you must use effective birth control.
- You must not have another active cancer, uncontrolled infection, or serious heart or bleeding problems.
- You must not have known severe allergies to the study drugs or certain other conditions like DPD deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests whether adding an EGFR-targeting antibody to chemotherapy can help people with colorectal cancer that has spread to the liver. It's for those whose tumors have a normal RAS gene and who have not had treatment before.
This trial tests a combination of three drugs (doxorubicin liposome, capecitabine, oxaliplatin, and bevacizumab) as a first treatment for advanced colorectal cancer that has a specific SMAD4 gene mutation. The goal is to see if this combination shrinks tumors and is safe for patients who have not had chemotherapy before.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
Hear when a new Advanced Colorectal Cancer (Part 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.